1. Scrip
  2. >>New Products

Incyte’s US Approval For PD-1 Inhibitor Zynyz In MCC Draws Muted Response

Unlikely To Prove Competitive

 
• By Ayisha Sharma

The US firm’s Zynyz has won accelerated approval for the treatment of first-line Merkel cell carcinoma, bouncing back from a prior regulatory setback, but its third-to-market status leaves it with the crumbs under the table in this orphan indication.  

Wooden background with three drawn emoticon images in middle: sad, neutral and happy. Hand reaching out to place neutral emoticon.
The Approval Milestone Was Met With A Neutral Response • Source: Shutterstock

Incyte Corporation’s PD-1 inhibitor, retifanlimab, has won a US approval in first-line Merkel cell carcinoma (MCC) under the brand name Zynyz, but analysts are unimpressed by its commercial potential given the availability of more competitive products and the rarity of MCC, ahead of approvals in other indications.

The US Food and Drug Administration approved Zynyz under an accelerated pathway based on tumor response rate and duration of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.